Oral caffeine pouches are a rapidly emerging nicotine-free stimulant product delivering caffeine through buccal absorption. Despite growing commercial availability and uptake among young people, peer-reviewed evidence on this product category remains extremely limited. This review aims to synthesize the available evidence on this product category and to assess whether a precautionary public health response may be warranted. Searches of PubMed, Scopus, and Google Scholar were supplemented by grey literature. Commercially available pouches contain 25-200 mg of caffeine per unit. Analogue evidence suggests buccal absorption may be faster than conventional oral ingestion. Biologically plausible risks from caffeine pharmacology and analogue products include cardiovascular stimulation, oral mucosal irritation, and acute caffeine toxicity, with adolescents and pregnant women at heightened risk. Caffeine pouches are classified as foods or dietary supplements in most jurisdictions, with no age-purchase restrictions or standardized dosing controls. In the absence of documented population-level harms, the rationale for early action rests on precautionary grounds: rapid market growth, high uncontrolled per-unit doses, and an established pattern of youth uptake of analogous oral pouch products. On this basis, coordinated regulatory oversight, dedicated empirical safety research, and targeted public health communication may be warranted before population-scale uptake.